Comparing two chemo drugs before radiation for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if a newer chemo pill (TAS-102) works better than the standard pill (capecitabine) when given before radiation and surgery for rectal cancer. It is for people with stage II or III rectal cancer that has certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have stage II or III rectal cancer that is within 12 cm of the anal opening and has at least one high-risk feature
- Be well enough to have a performance status of 0 or 1 (able to carry on normal activities)
- Tumor must be measurable on scans
- No other current or past cancers except certain skin or cervical cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
This trial is testing a new drug combined with radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests whether a newer approach can treat early-stage rectal cancer without removing the whole rectum, aiming to preserve bowel function. It compares different treatment options to see which is safest and most effective.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.